Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?
Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?
Created by
Presenter
Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular ProgramsBrigham and Women’s HospitalHeart and Vascular CenterProfessor of Medicine, Harvard Medical SchoolBoston, USA